CFDE Data Portal | Search POU5F1P4

	Label	Description
	POU5F1P4 associations Collection (Entity type)	Associations for POU5F1P4_associations
	POU5F1P4 associations.tsv File (Entity type)	A file from IDG as part of the Harmonizome project
	POU5F1P4 Gene (Entity type)	ENSG00000237872 - POU class 5 homeobox 1 pseudogene 4
	GSE148200 0 V 2 GEMCITABINE HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE226249 5 V 4 PIRFENIDONE HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE228106 3 V 5 PACLITAXEL HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE119369 H10 inhibition 1 v 5 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE137325 2 V 0 COPANLISIB HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE146358 dopamine 5 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE202434,GSE202438 2 V 14 TALAZOPARIB HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS

POU5F1P4 associations

Associations for POU5F1P4_associations

POU5F1P4 associations.tsv

A file from IDG as part of the Harmonizome project

POU5F1P4

ENSG00000237872 - POU class 5 homeobox 1 pseudogene 4

GSE148200 0 V 2 GEMCITABINE HUMAN UP

A Gene Set from LINCS

GSE226249 5 V 4 PIRFENIDONE HUMAN DN

A Gene Set from LINCS

GSE228106 3 V 5 PACLITAXEL HUMAN DN

A Gene Set from LINCS

GSE119369 H10 inhibition 1 v 5 human up

A Gene Set from LINCS

GSE137325 2 V 0 COPANLISIB HUMAN UP

A Gene Set from LINCS

GSE146358 dopamine 5 v 1 human up

A Gene Set from LINCS

GSE202434,GSE202438 2 V 14 TALAZOPARIB HUMAN DN

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.